Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.

STUDY OBJECTIVES This post hoc analysis evaluated the time to response that can be expected with sodium oxybate (SXB) for treatment of excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy. METHODS Data were from a 4-week, double-blind, randomized, placebo-controlled trial (GHB-2; N = 136) of oral SXB 3 g, 6 g, and 9 g nightly, and its 12-month open-label extension (GHB-3). Two response definitions were utilized: ≥ 20% improvement in Epworth Sleepiness Scale (ESS) score (EDS responders), and ≥ 50% reduction in weekly cataplexy attacks (cataplexy responders). These thresholds were previously determined to be clinically relevant based on analysis of the relationship of Clinical Global Impression of Change with ESS and number of cataplexy attacks. Kaplan-Meier curves and median times to first response, based on above criteria, and to maximum response were estimated. RESULTS Among 86 patients randomized to SXB in GHB-2 and continued into GHB-3, 77.6% and 90.7% were EDS and cataplexy responders, respectively. The median (95% CI) times to first response were 37 (31-50) days for EDS and 25 (17-29) days for cataplexy, and median times to maximum response were 106 (85-164) days for EDS and 213 (94-279) days for cataplexy. GHB-3 results among 31 patients initially randomized to placebo were consistent with those treated with SXB throughout, but with longer times to maximum response. CONCLUSIONS Response onset, assessed as clinically meaningful improvements in EDS and cataplexy, was observed in most patients within 2 months; a longer period is needed to achieve maximum response. Clinicians should recognize that time to initial and maximum response may take weeks to months.

[1]  M. Thorpy,et al.  Delayed diagnosis of narcolepsy: characterization and impact. , 2014, Sleep medicine.

[2]  F. García-García,et al.  Narcolepsy as an Immune-Mediated Disease , 2014, Sleep disorders.

[3]  R. Rosenberg,et al.  The AWAKEN Survey: Knowledge of Narcolepsy among Physicians and the General Population , 2014, Postgraduate medicine.

[4]  E. Mignot.  A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes , 2012, Neurotherapeutics.

[5]  Cathy Alessi,et al.  Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. , 2007, Sleep.

[6]  J. Black,et al.  Sodium oxybate improves excessive daytime sleepiness in narcolepsy. , 2006, Sleep.

[7]  R. Chervin.  Epworth sleepiness scale? , 2003, Sleep medicine.

[8]  R. Stafford,et al.  Principles and Practice of Sleep Medicine , 2001 .

[9]  M. Johns,et al.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale. , 1991, Sleep.

[10]  Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. , 2005, Sleep medicine.

[11]  The Xyrem®,et al.  A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. , 2005, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[12]  U.S.Xyrem® Multicenter Study Group.  Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. , 2004, Sleep medicine.

[13]  U. S. Xyrem,et al.  A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. , 2003, Sleep.

[14]  A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. , 2002, Sleep.